TITLE

Pharma says acquisition is the right prescription

AUTHOR(S)
Speizer, Irwin
PUB. DATE
October 2003
SOURCE
Business North Carolina;Oct2003, Vol. 23 Issue 10, p22
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the merger of drug company aaiPharma Inc. with Cima Labs Inc. in 2003. Basis of the consolidation; Impact of the merger on the companies' stock performance; Changes after the merger.
ACCESSION #
10972782

 

Related Articles

  • CIMA/aaiPharma Tie the Pharmaceutical Knot.  // High Yield Report;8/11/2003, Vol. 14 Issue 32, p1 

    Reports on the proposed merger between U.S.-based pharmaceutical companies aaiPharma and CIMA. Impact of the proposed merger on the financial conditions of the drug manufacturing industry; Estimated capital of the merged companies; Financial standings of the two pharmaceutical companies.

  • aaiPharma to acquire rival Cima Labs.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p19 

    Reports on the intention of aaiPharma Inc. to acquire Cima Labs Inc. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the pharmaceutical biotechnology industry.

  • Cima Leaves aaiPharma for Cephalon.  // Chemical Market Reporter;11/10/2003, Vol. 264 Issue 16, p2 

    Reports on the ownership and control of the drug delivery technology platform, Cima Labs Inc. won by drug company, Cephalon Inc. over aaiPharma Inc. Terms and details of the stock purchase; Operations and financial performance of the companies; Stock price.

  • Cephalon to acquire Cima Labs for $515 million.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p22 

    Reports on the plan of Cephalon Inc. to acquire Cima Labs Inc. in the U.S. Value of deal; Terms under the planned acquisition; Benefits of the acquisition for both companies.

  • NSP and Enzon to Merge in $1.6 Billion Deal.  // Chemical Market Reporter;2/24/2003, Vol. 263 Issue 8, p2 

    Reports on the merger between the U.S.-based pharmaceutical companies, NSP Pharmaceuticals Inc. and Enzon Pharmaceuticals Inc. involving a stock-for-stock transaction. Details about the deal; Financial performance of the companies; Implications for the pharmaceutical industry.

  • Xanodyne Acquires aaiPharma Assets. Koroneos, George // Pharmaceutical Technology;Aug2005, Vol. 29 Issue 8, p18 

    Reports on the acquisition of the pharmaceuticals division of aaiPharma Inc. by Xanodyne Pharmaceuticals Inc. in the U.S. Amount involved in the acquisition transaction; Pain-management drugs that Xanodyne will acquire based on the deal; Revenue expected to be generated from the addition of the...

  • Hardball Over a Breakup Fee. Sikora, Martin // Mergers & Acquisitions: The Dealermaker's Journal;Sep2004, Vol. 39 Issue 9, p3 

    Reflects on the lawsuit filed by CIMA Labs Inc. against aaiPharma Inc. for fraud and breach of contract. Demands of CIMA; Issues behind the lawsuit filed by CIMA; Effect of breakup fee on the bidding process.

  • Cephalon Maintains CIMA Takeout Will Fly. Cohen, Judy Radler // Mergers & Acquisitions Report;4/12/2004, Vol. 17 Issue 15, p1 

    Discusses the status of the acquisition deal between Cephalon Inc. and CIMA Laboratories Inc. Amount of money involved in the deal; Tender offer of Cephalon Inc. for the shares of CIMA; Information on the two fentanyl products from CIMA Laboratories Inc. that Cephalon Inc. wants to acquire;...

  • M&A Activity Shifts from Pharma to Biotech.  // Applied Clinical Trials;Nov2003, Vol. 12 Issue 11, p43 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics